Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elias Kaufmann"'
Autor:
Andy Yi An, Arjun Baghela, Peter G. Y. Zhang, Travis M. Blimkie, Jeff Gauthier, Daniel Elias Kaufmann, Erica Acton, Amy H. Y. Lee, Roger C. Levesque, Robert E. W. Hancock
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionPersistent symptoms after COVID-19 infection (“long COVID”) negatively affects almost half of COVID-19 survivors. Despite its prevalence, its pathophysiology is poorly understood, with multiple host systems likely affected. Here, we f
Externí odkaz:
https://doaj.org/article/847c7a1bfa6448129c35b711a7569eb0
Publikováno v:
The Journal of organic chemistry. 83(13)
The commercial macrolide antibiotic fidaxomicin was synthesized in a highly convergent manner. Salient features of this synthesis include a β-selective noviosylation, a β-selective rhamnosylation, a ring-closing metathesis, a Suzuki coupling, and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d168690a43dda75c2fd130c524f1de19
https://pubmed.ncbi.nlm.nih.gov/29590752
https://pubmed.ncbi.nlm.nih.gov/29590752
Publikováno v:
Organic Letters
Org. Lett.
Org. Lett.
The first enantioselective total synthesis of fidaxomicin, also known as tiacumicin B or lipiarmycin A3, is reported. This novel glycosylated macrolide antibiotic is used in the clinic for the treatment of Clostridium difficile infections. Key featur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a1b1e438530285098748a476835fa02
http://pubs.acs.org/doi/abs/10.1021/acs.orglett.5b01602
http://pubs.acs.org/doi/abs/10.1021/acs.orglett.5b01602
Publikováno v:
Angewandte Chemie. 127:1953-1956
Fidaxomicin, auch Tiacumicin B oder Lipiarmycin A3 genannt, ist ein neuartiges makrocyclisches Antibiotikum, das klinisch gegen Clostridium-difficile-Infektionen eingesetzt wird. Dieser Naturstoff zeigt zudem eine exzellente Aktivitat gegen multiresi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ae97b9c7a123ca8c8bf1119bdce2084
https://doi.org/10.1002/ange.201409464
https://doi.org/10.1002/ange.201409464
Publikováno v:
Angewandte Chemie-International Edition
Fidaxomicin, also known as tiacumicin B or lipiarmycin A3, is a novel macrocyclic antibiotic that is used in hospitals for the treatment of Clostridium difficile infections. This natural product has also been shown to have excellent bactericidal acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf2f08097fad4d3ac8204703f117ac1
https://doi.org/10.1002/anie.201409464
https://doi.org/10.1002/anie.201409464